News | Cardiac Diagnostics | August 07, 2015

Boehringer Ingelheim to Sponsor ACC-Led Diabetes Collaborative Registry

Pharmaceutical company becomes latest participant in national data repository for coordinated care of diabetes patients

ACC, Boehringer Ingelheim, Diabetes Collaborative Registry, American College of Cardiology

August 7, 2015 — The American College of Cardiology (ACC) has announced that Boehringer Ingelheim is the newest industry sponsor of The Diabetes Collaborative Registry. The registry is an interdisciplinary effort led by the college in partnership with the American Diabetes Association, the American College of Physicians, the American Association of Clinical Endocrinologists and the Joslin Diabetes Center.

“Heart disease is the leading cause of death for people with diabetes,” said American College of Cardiology President Kim Allan Williams, M.D., FACC. “Their unique needs call for cross-specialty care that will be made possible through the Diabetes Collaborative Registry, and we thank Boehringer Ingelheim for joining the effort to support the continued, accelerated growth of this registry.”

Since the official launch of the Diabetes Collaborative Registry just one year ago, interest and participation in the program has exceeded expectations. To date, more than 100 cross-specialty practice entities have enrolled in the registry, expanding an already robust national footprint spanning nearly 500 practice locations with 1,300 providers across 28 states.

Additional support will allow the registry to scale up and increase its impact, including outreach to and enrollment of a larger installation base of practices and health systems, enhanced quality improvement performance reports delivered to participants, and more data collection to drive actionable insights and decision-making to improve the quality of care delivered to the right patients at the right time.

The Diabetes Collaborative Registry aspires to create the largest single repository of real-world clinical information on diabetes and cardiometabolic care in the world to improve the quality of life for all people living with these conditions.

Patients with diabetes often receive treatments across multiple medical specialties for a multitude of related conditions. The Diabetes Collaborative Registry will allow for a longitudinal study of diabetes across all stages of the disease—including presentation, progression, management and outcomes—even as patients receive treatment from multidisciplinary care teams. It will also incorporate the growing number of patients with diabetes in the ACC’s PINNACLE Registry, which is the nation’s largest ambulatory cardiovascular registry.

Participation in the registry is expected to yield long-term benefits for practices, providers and patients, as physicians can track adherence and performance against evidence-based national metrics and benchmarks at the provider, practice and site level through regular reports received; can identify potential areas to target for quality improvement opportunities; may meet requirements for federal incentive reporting programs, such as the Centers for Medicare and Medicaid Services’ Physician Quality Reporting System and Electronic Health Care Record Incentive Program; and will, ultimately, transform the quality of care provided to patients across the continuum of ambulatory primary and specialty care.

Researchers will have the opportunity to gather insights from this repository of diabetes care data from various providers in outpatient settings, and patients will benefit from their physicians’ increased access to a central repository of diabetes data based on the latest science and research that can be used to tailor their care. The registry maintains an aggressive outcomes research agenda and is anticipated to complete a number of research abstracts and manuscripts by the conclusion of this year.

For more information: www.acc.org

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
NIAID Scientists Illuminate Mechanism of Increased Cardiovascular Risks With HIV
News | Cardiac Diagnostics| September 14, 2017
September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic i
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init